LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
April 26, 2023 08:00 ET
|
LianBio
• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with...
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
December 19, 2022 07:00 ET
|
LianBio; Pfizer Inc.
Pfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive a $20 million upfront payment, to be released from...
LianBio Announces President and Chief Strategy Officer Departure
December 13, 2022 17:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 16:05 ET
|
LianBio
Enrollment completed in registrational Phase 3 EXPLORER-CN trial of mavacamten, with data expected mid-2023Mavacamten patient education and physician awareness activities underway in China with...
LianBio to Participate in Upcoming Investor and Industry Events
November 10, 2022 08:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors
November 09, 2022 16:05 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
November 01, 2022 16:05 ET
|
LianBio
• LIBRA trial designed to support registration in China• Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq:...
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 16:05 ET
|
LianBio
Completed enrollment in China Phase 3 trial of mavacamten; topline data expected mid-2023 Submitted mavacamten New Drug Application (NDA) in Singapore Submitted infigratinib NDA in Hong Kong Three...
LianBio to Participate in June Investor Events
June 02, 2022 16:02 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 08:00 ET
|
LianBio
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3...